Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Garth Richmond who wrote (378)	1/7/1999 4:54:00 PM
From: Ian@SI	Respond to of 1321

I missed this in all the AMD phase III trial results excitement... January 6, 1999 QLT Phototherapeutics Gets UK Govt Ok To Mkt Photofrin Pdt VANCOUVER (Dow Jones)--QLT PhotoTherapeutics Inc. (QLTIF) said health authorities in the U.K. have cleared marketing of the company's Photofrin product for the palliative treatment of late-stage lung cancer and advanced esophageal cancer. In a news release, QLT said that specifically, U.K. regulators cleared Photofrin for the palliation of obstructing endobronchial nonsmall cell lung cancer, and the palliative treatment of obstructing esophageal cancers. The company said Beaufour Ipsen is currently marketing Photofrin in France, Germany and the Netherlands. Additional applications remain pending in nine other European countries. When used to treat late-stage lung cancer or advanced esophageal cancer, Photofrin is first injected into a patient intravenously. Within 48 hours, the light-activated drug selectively concentrates in tumor cells, while largely clearing from normal tissue, the company said. Activation of Photofrin by a non-thermal laser light at the tumor site produces a toxic form of oxygen that destroys the cancer cells, QLT said. QLT PhotoTherapeutics develops and commercializes proprietary pharmaceutical products for use in photodynamic therapy.